IOL Chemicals Reports Strong Q2 & H1 FY26 Results with Margin Expansion
IOL Chemicals & Pharma announced Q2 & H1 FY26 results with revenue up 7.9% & 8.9% YOY respectively. EBITDA increased by 33.3% & 25.7% YOY respectively. They also incorporated IOL Pharmaxis UK Limited.
The financial performance indicates stable growth and margin expansion. The strategic initiatives will likely have a moderate impact on the company's future prospects.
The announcement highlights positive financial results, including revenue and profit growth, along with strategic initiatives like international expansion and new certifications.
* IOL Chemicals & Pharmaceuticals Ltd. announced its financial results for the quarter and half year ended 30th September 2025. * Q2 FY26 (Standalone): Revenue from Operations at ₹ 567.5 crore, up 7.9% Y-o-Y; EBITDA at ₹ 64.0 crore, up 33.3% Y-o-Y; and Profit After Tax at ₹ 30.0 crore, up 56.7% Y-o-Y. * H1 FY26 (Standalone): Revenue from Operations at ₹ 1,119.2 crore, up 8.9% Y-o-Y; EBITDA at ₹ 133.5 crore, up 25.7% Y-o-Y; and Profit After Tax at ₹ 64.0 crore, up 31.0% Y-o-Y. * EBITDA margin improved to 11.1% in Q2 FY26 from 9.0% in Q2 FY25. * Received EDQM’s Certificate of Suitability for Pantoprazole Sodium Sesquihydrate Process -III on 14th October 2025, enabling exports to Europe and CEP-compliant markets. * Incorporated IOL Pharmaxis UK Limited in October 2025 to strengthen international operations. * Management Commentary: Q2 FY26 reflects IOL’s continued operational strength and strategic focus, with revenue from operations rising 7.9% and EBITDA improving 33.3% year-on-year.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.